Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Exenatide 10 ug subcutaneous twice daily Exenatide 10 ug BID	none; lifestyle: intensive	80	73	48
A2	Placebo Placebo	structured diet and physical activity program; lifestyle: intensive	83	79	54

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Exenatide 10 ug subcutaneous twice daily A1	Placebo A2	Whole trial ALL
age	mean (years)	47.01	45.15
age	sd (years)	10.95	12.74
bmi	mean (kg/m2)	39.64	39.39
female	n	58	67
hba1c	mean (percent)	5.61	5.58
other igt or ifg	n			38
other igt or ifg	percent			25
weight	mean (kg)	109.5	107.6

18 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

Percent body weight change (1 lines; O10)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
24	A1 vs A2	md	-3.3 percent	0.5			not stated; modified itt; R0026955:Results

Weight loss of 5 percent or more (2 lines; O11A)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
24	A1	responders	31.5			73	not stated; modified itt; registry:outcomes
24	A2	responders	16.5			79	not stated; modified itt; registry:outcomes

Progression to type 2 diabetes (2 lines; O14)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				3 / 65	not stated; modified itt; registry:outcomes
	A2	events				2 / 65	not stated; modified itt; registry:outcomes

All cause mortality (2 lines; O20)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				0 / 73	not stated; modified itt; R0026955:Results
	A2	events				0 / 79	not stated; modified itt; R0026955:Results

Serious adverse events (2 lines; O25)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				0 / 73	not stated; safety; registry:adverse_events
	A2	events				0 / 79	not stated; safety; registry:adverse_events

Discontinuation due to adverse events (2 lines; O26)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				9 / 80	not stated; randomized; registry:flow
	A2	events				3 / 83	not stated; randomized; registry:flow

Nausea (2 lines; O27A)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				18 / 73	not stated; safety; registry:adverse_events
	A2	events				3 / 79	not stated; safety; registry:adverse_events

Vomiting (2 lines; O27B)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				6 / 73	not stated; safety; registry:adverse_events
	A2	events				1 / 79	not stated; safety; registry:adverse_events

Diarrhea (2 lines; O27C)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				10 / 73	not stated; safety; registry:adverse_events
	A2	events				2 / 79	not stated; safety; registry:adverse_events

Discontinuation due to gastrointestinal adverse events (1 lines; O27E)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				5 / 80	not stated; randomized; R0026955:Results